ERBB2 and gastric cancer: Rha Rha SY SY Oh Oh D-Y D-Y Yañez Yañez P P Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Lancet Oncol Lancet Oncol 2023 2023 24 24 1181 1181 1195 1195 10.1016/S1470-2045(23)00515-6 10.1016/S1470-2045(23)00515-6 supplied-pmid 37875143?